Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 28, 2019

First Patient Dosed in Trial of ADCT-402/Imbruvica Combo for Advanced DLBCL, MCL

News

A Phase 1 trial testing the combination of ADCT-402 (loncastuximab tesirine) with Imbruvica (ibrutinib) for advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) has dosed the first patient. Patient ... Read more

February 13, 2019February 14, 2019

Stand Up To Cancer’s ‘Dream Team’ to Investigate Devimistat Combo Therapy for T-cell Lymphoma

News

Rafael Pharmaceuticals‘ devimistat (CPI-613) — which targets the metabolic alterations in cancer cells — will be studied as part of a combination therapy for the treatment of T-cell lymphoma, the company announced. ... Read more

January 31, 2019

FDA Approves Imbruvica-Gazyva Combo for First-line Treatment of CLL/SLL

News

The U.S. Food and Drug Administration has approved a combination of Imbruvica (ibrutinib) and Gazyva (obinutuzumab) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This is the first ... Read more

January 28, 2019

FDA Names Umbralisib ‘Breakthrough Therapy’ as Possible Treatment for Marginal Zone Lymphoma

News

The U.S. Food and Drug Administration (FDA) has designated umbralisib (TGR-1202), by TG Therapeutics, a breakthrough therapy as a possible treatment for adults with marginal zone lymphoma (MZL) who did not respond to at least one ... Read more

January 18, 2019

Tyvyt, PD-1 Inhibitor Newly Approved in China, Showed Efficacy Similar to Opdivo and Keytruda, Trial Data Show

News

The immune checkpoint inhibitor Tyvyt (sintilimab injection) reduced tumor burden in eight out of 10 people with relapsed or refractory classic Hodgkin’s lymphoma taking part in a Phase 2 clinical ... Read more

January 8, 2019

Tyvyt Approved in China for Previously Treated Classical Hodgkin’s Lymphoma

News

Tyvyt (sintilimab injection), an immune checkpoint inhibitor jointly developed by Innovent Biologics and Eli Lilly and Company in China, is now available as a therapy for patients with classical Hodgkin’s lymphoma who failed to respond ... Read more

December 7, 2018

Generon Set to Begin Phase 1 Trial of A-319 in Patients With B-cell Cancers in China

News

China’s regulatory agency has approved the launch of Generon‘s Phase 1 clinical trial to test its immunotherapy candidate, A-319, in patients with acute lymphoblastic leukemia (ALL) and B-cell lymphoma. Approval of ... Read more

November 30, 2018

First Patient Dosed in Phase 3 Trial of BeiGene’s Zanubrutinib for Hard-to-Treat Leukemia, Lymphoma

News

The global Phase 3 trial evaluating BeiGene’s investigational Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has started dosing patients. The study (NCT03734016) is recruiting patients who failed ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). ... Read more

November 9, 2018

Seattle Genetics Seeks Adcetris Approval as First-Line Combo Treatment for Peripheral T-cell Lymphomas

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment for patients with ... Read more